Virtual screening based on pharmacophore to discover host ER alpha- glucosidase II inhibitor for dengue therapy

Elsafira Ariavianti, Filia Stephanie, Usman Sumo Friend Tambunan

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

1 Citation (Scopus)


Dengue is one of the crucial diseases in human-caused by dengue virus (DENV) infection. However, the development of DENV antiviral is often facing a problem because no effective drug to treat infection caused by all DENV serotypes. The inhibition of host protein involved in DENV life cycle can be a potential approach in dengue drug discovery, and also avoiding antiviral resistance. Endoplasmic Reticulum (ER) alpha-glucosidase II is one of the target host protein in DENV endoplasmic reticulum that plays an important role in the maturation process of DENV envelope glycoprotein. In this research, pharmacophore-based virtual screening and molecular docking simulations were performed to find ligand that has potential to inhibit alpha-glucosidase II activity. About 67,609 natural products from InterBioScreen (IBS) database were used in the simulation as ligands with alpha-glucosidase II as the protein target. After subjected to Lipinski’s Rule of Five, drug-likeness, nasty functions, and toxicity screening using DataWarrior software, 17,462 ligands were obtained. The pharmacophore features for molecular docking simulation was obtained from Protein-Ligand Interaction Fingerprint (PLIF) analysis using eight alpha-glucosidase II protein with different ligands. Based on virtual screening, rigid, and flexible docking simulations using Molecular Operating Environment (MOE) software, 32 ligands have lower Gibbs free binding energy (ΔGbinding) compared to the standards. The best ligand, namely STOCK1N-86400 which belongs to alkaloid derivative, showed the exceptional ligand interaction and had the lowest ΔGbinding of - 10.276 kcal/mol. The ligand was identified to have a binding interaction with amino acid Asp564 and Asp640 in alpha-glucosidase II catalytic site. The STOCK1N-86400 was also identified to have good pharmacological properties after subjected to ADME-tox test using Toxtree, SwissADME, admetSAR, and pkCSM software.

Original languageEnglish
Title of host publicationSymposium of Materials Science and Chemistry II
EditorsTutik Dwi Wahyuningsih, Roto Roto, Dwi Siswanta, Rohana Adnan, Laurent Commeiras, Kuwat Triyana, Kuwat Triyana, Indriana Kartini, Julius Motuzas
PublisherTrans Tech Publications Ltd
Number of pages9
ISBN (Print)9783035716139
Publication statusPublished - 1 Jan 2020
Event5th International Conference on Science and Technology, ICST 2019 - Yogyakarta, Indonesia
Duration: 30 Jul 201931 Jul 2019

Publication series

NameKey Engineering Materials
Volume840 KEM
ISSN (Print)1013-9826
ISSN (Electronic)1662-9795


Conference5th International Conference on Science and Technology, ICST 2019


  • Dengue virus
  • Host ER alpha-glucosidase II
  • InterBioScreen database
  • Natural products
  • Pharmacophore


Dive into the research topics of 'Virtual screening based on pharmacophore to discover host ER alpha- glucosidase II inhibitor for dengue therapy'. Together they form a unique fingerprint.

Cite this